PostIPO

HOSTED BY     BNYMellon

POST-IPO EQUITY RAISE OF THE YEAR  

 
This award recognises a company that has successfully completed a significant, impactful or transformational secondary placement or follow-on equity raise (not debt) on any international exchange.
 
It is open to public European life science companies only.

Qualifying criteria

- Must be a public company
- Must have raised the funds in the period between 1 September 2018 to 1 September 2019
- Must be a company with a European headquarters
- Raise must be a secondary placement or follow-on NOT an IPO

Judges will be paying particular attention to:

- Amount and type of funds raised
- Process / speed / allocation fulfilment of securing of significant new funds
- Level / reputation of investor(s) attracted
- Post-finance allocation / use of proceeds
- Level of value creation / value realisation from raise
 
 
 
BUY TICKETS AND TABLES
 
 

2019 FINALISTS

 

Ascendis Pharma

Ascendis Pharma, Denmark

Biocartis

Biocartis, Belgium

Calliditas Therapeutics

Calliditas Therapeutics, Sweden

Hansa Biopharma

Hansa Biopharma, Sweden

Immunicum

Immunicum, Sweden

Kiadis Pharma

Kiadis Pharma, The Netherlands

BUY TICKETS AND TABLES